Nucor earnings beat by $0.08, revenue fell short of estimates
Investing.com -- Fresenius (ETR:FREG) shares fell 2% on Tuesday after the company announced its new ’Reignite’ strategy ahead of its Capital Markets Day.
The company set a mid-term target of reaching an adjusted EBIT margin in the "mid-teens" by 2030.
This compares to a consensus forecast of 11.9%. The margin targets apply across all its divisions, with Care Delivery and Care Enablement both aiming for "mid-teens %" margins and Value-Based Care targeting a "LSD %" margin by 2030.
Fresenius also announced an additional €300 million in cost savings, raising its total savings target under the FME25+ program to €1.05 billion by 2027.
This is up from the previous target of €750 million for 2025, which itself was increased from an initial goal of €500 million.
The company projects global market volume growth of 4-5% annually in patient numbers between 2025 and 2035, while the U.S. market is expected to grow by 2% annually over the same period.
Fresenius lowered its leverage target to 2.5-3x, down from the previous 3-3.5x range. It plans to invest €800-1,000 million in capital expenditures annually from 2025 through 2030.
The dividend payout ratio is set at 30-40% of adjusted net income, and the company introduced an initial €1 billion share buyback program scheduled between 2025 and 2027.